Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Protagonist Therapeutics

Protagonist Therapeutics (NASDAQ: PTGX) insider transactions

In the twelve months to 10 November 2026, executives and directors of Protagonist Therapeutics reported 36 open-market sales of 775,853 shares ($87.7m) and 0 open-market purchases, by 7 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Protagonist Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
30 September 2026Ali AsifChief Financial OfficerOption exercise, 10b5-1 plan+9,229$38.9868,232Form 4
30 September 2026Ali AsifChief Financial OfficerOption exercise, 10b5-1 plan+28,438$23.4296,670Form 4
30 September 2026Ali AsifChief Financial OfficerOption exercise, 10b5-1 plan+15,650$19.19112,320Form 4
30 September 2026Ali AsifChief Financial OfficerOption exercise, 10b5-1 plan+5,312$12.17117,632Form 4
30 September 2026Ali AsifChief Financial OfficerOpen-market sale, 10b5-1 plan−12,595$141.77105,037Form 4
30 September 2026Ali AsifChief Financial OfficerOpen-market sale, 10b5-1 plan−46,034$141.7859,003Form 4
10 September 2026Patel Dinesh V PH DPresident and CEOOption exercise, 10b5-1 plan+7,278$21.58530,246Form 4
10 September 2026Patel Dinesh V PH DPresident and CEOOpen-market sale, 10b5-1 plan−7,278$144.10522,968Form 4
9 September 2026Patel Dinesh V PH DPresident and CEOOption exercise, 10b5-1 plan+63,548$21.58586,516Form 4
9 September 2026Patel Dinesh V PH DPresident and CEOOpen-market sale, 10b5-1 plan−63,548$146.18522,968Form 4
8 September 2026Patel Dinesh V PH DPresident and CEOOption exercise, 10b5-1 plan+54,174$21.58577,142Form 4
8 September 2026Patel Dinesh V PH DPresident and CEOOpen-market sale, 10b5-1 plan−54,174$145.87522,968Form 4
3 September 2026Patel Dinesh V PH DPresident and CEOGift−510—522,968Form 4
11 August 2026Patel Dinesh V PH DPresident and CEOOption exercise, 10b5-1 plan+34,239$21.58557,717Form 4
11 August 2026Patel Dinesh V PH DPresident and CEOOpen-market sale, 10b5-1 plan−34,239$148.52523,478Form 4
10 August 2026Patel Dinesh V PH DPresident and CEOOption exercise, 10b5-1 plan+65,761$21.58589,239Form 4
10 August 2026Patel Dinesh V PH DPresident and CEOOpen-market sale, 10b5-1 plan−65,761$149.11523,478Form 4
23 June 2026Waddill William D.DirectorOption exercise, 10b5-1 plan+9,000$16.5416,825Form 4
23 June 2026Waddill William D.DirectorOpen-market sale, 10b5-1 plan−9,000$117.947,825Form 4
10 June 2026Waddill William D.DirectorOption exercise, 10b5-1 plan+3,000$11.8010,825Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Protagonist Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.